iSpecimen (ISPC) vs MDxHealth SA (MDXH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MDxHealth SA is the larger company by market cap ($55.4 million vs $2.7 million), about 20.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ISPC | MDXH |
|---|---|---|
| Share price | $1.09 | $0.5805 |
| Market cap | $2.75M | $55.39M |
| 1-day change | -0.91% | -3.22% |
| YTD return | — | -83.74% |
| 1-year return | — | -87.16% |
| EPS (TTM) | $-52.98 | $-0.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $37.60 | $5.33 |
| 52-week low | $1.02 | $0.40 |
| Distance from 52-week high | -97.10% | -89.11% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +210.08% |
| Average volume | 667.50K | 5.69M |
| Shares outstanding | 2.52M | 95.42M |
| Employees | 7 | 364 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MDxHealth SA is about 20.2 times larger than iSpecimen by market value ($55.39M vs $2.75M).
About iSpecimen
ISPC stock →iSpecimen Inc. operates marketplace that provides biospecimens to life science researchers in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 7 employees
About MDxHealth SA
MDXH stock →MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.
Health Care · Medical Specialities · 364 employees
ISPC vs MDXH FAQ
Which is bigger, iSpecimen or MDxHealth SA?
MDxHealth SA (MDXH) is larger, with a market capitalization of $55.39M compared with $2.75M for iSpecimen (ISPC).
Are iSpecimen and MDxHealth SA in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Commercial Physical & Biological Resarch for iSpecimen and Medical Specialities for MDxHealth SA.